Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Exreprotein is a specialized biotechnology company based in Suzhou, China, that focuses on the development and large-scale manufacture of high-quality recombinant proteins and cytokines. As a core brand of Excell Bio, the company provides GMP-grade raw materials that are essential for the research, development, and commercial production of cell and gene therapies (CGT). Their extensive product portfolio includes growth factors, interleukins, and enzymes produced through advanced microbial and mammalian expression platforms. Exreprotein's facilities are designed to meet international quality standards, ensuring high purity, bioactivity, and batch-to-batch consistency for clinical applications. The company serves a global clientele, supporting the advancement of immunotherapies and regenerative medicine. By bridging the gap between laboratory research and industrial-scale production, Exreprotein plays a vital role in the biopharmaceutical supply chain.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Exreprotein.